To overcome the challenges faced during bioprocess development, the following strategies were employed:
: The study shifts the focus from "testing quality into the product" to "building quality into the process" through deep scientific understanding.
: It defines CQAs (e.g., aggregates, galactosylation, and host cell protein) and uses a "Continuum of Criticality" to rank their impact on safety and efficacy. A Mab A Case Study In Bioprocess Development
: Researchers from Penn State, the FDA, and Takeda developed an innovative approach to replace the expensive Protein A capture step entirely. They linked single-pass tangential-flow filtration (SPTFF) and high-performance countercurrent membrane purification (HPCMP) to precondition mAb harvests. This integrated system continuously concentrated clarified cell culture fluid 20-fold (up to ~56 g/L mAb), cut host cell proteins by ~60% , reduced DNA impurities more than 30-fold , and maintained ~94% antibody yield .
: It helped popularize the "platform approach" in mAb production, which significantly reduces the time from gene to clinical trials. Critiques & Limitations with their FCCM™ platform
Continuous processing offers transformative benefits. By linking upstream perfusion bioreactors directly to downstream multi-column chromatography (MCC), the entire manufacturing process runs uninterrupted. This leads to a more homogeneous product, significantly reduced equipment footprint (70% smaller, by some estimates), and dramatic cost reductions. Continuous processing can achieve up to 35% cost savings compared to batch methods for annual productions of 100–500 kg. Companies like Enzene, with their FCCM™ platform, have already achieved mAb production costs of less than $40 per gram, a fraction of the $150-300 per gram typical of fed-batch processes.
: It demonstrates how to use systematic risk assessments (like FMEA) to justify process parameters and ranges. significantly reduced equipment footprint (70% smaller
[QTPP Definition] ➔ [Identify CQAs] ➔ [Define CPPs] ➔ [Establish Control Strategy]
: Implementing risk management and real-time monitoring to ensure consistent quality throughout the product lifecycle. Key Stages in the A-Mab Bioprocess Development 1. Defining Critical Quality Attributes (CQAs)
The production process included a dedicated after elution.
